Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about SNY, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Imiglucerase FDA approved May 1994 · Cerezyme |
Gaucher's Disease Type III | Phase 3 · NCT07927140 | Not yet recruiting |
| Rilzabrutinib FDA approved Aug 2025 · Wayrilz |
Immune Thrombocytopenia | Phase 3 · NCT07216079 | Active not recruiting |
| Teriflunomide FDA approved Sep 2012 · Aubagio |
Multiple Sclerosis | Phase 3 · NCT07930624 | Not yet recruiting |
| Plerixafor FDA approved Dec 2008 · Mozobil |
Diffuse Large B-cell Lymphoma (DLBCL) | Phase 2 · NCT02570542 | Active not recruiting |
| Isatuximab FDA approved Mar 2020 · Sarclisa |
Plasma Cell Myeloma Refractory | Phase 1/2 · NCT04643002 | Recruiting |
| Insulin FDA approved Apr 2000 · Lantus Solostar |
Type 1 Diabetes Mellitus | Phase 2 · NCT06111586 | Active not recruiting |
| Alglucosidase Alfa FDA approved Apr 2006 · Myozyme |
Glycogen Storage Disease Type II | N/A · NCT04848779 | Completed |
| Efanesoctocog Alfa | Factor VIII Deficiency | Phase 4 · NCT06941870 | Recruiting |
| NVXC19 (EU licensed, standalone) | Immunization | Phase 3 · NCT07890454 | Recruiting |
| Frexalimab | Multiple Sclerosis | Phase 3 · NCT06141486 | Active not recruiting |
| IIV-HD + NVXC19 combination | Immunization | Phase 3 · NCT07890454 | Recruiting |
| IVIg | Chronic Inflammatory Demyelinating Polyneuropathy | Phase 3 · NCT06290141 | Recruiting |
| Lunsekimig | Chronic Obstructive Pulmonary Disease | Phase 3 · NCT07190209 | Recruiting |
| Measles, combinations with mumps and rubella… | Yellow Fever Immunization | Phase 3 · NCT07103148 | Active not recruiting |
| monovalent Hep B vaccine | Haemophilus Influenzae Type b Immunisation | Phase 3 · NCT07941622 | Not yet recruiting |
| MRI contrast-enhancing agents | Multiple Sclerosis | Phase 3 · NCT06141486 | Active not recruiting |
Also used in these trials (approved or third-party drugs, not SNY's own candidates): Belumosudil, Saponin-based Adjuvant, Gemcitabine Hydrochloride, Paclitaxel, Pemetrexed Disodium, Teplizumab, Cemiplimab, Cisplatin, Cholestyramine, Carboplatin, Belantamab Mafodotin, Pomalidomide.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
SNY holds $6B in cash and short-term investments and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when SNY files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| AMUNDI | Institution (13G, 5%+) | 68,832,052 | 5.64% | 2026-09-30 |
| Dodge & Cox Inc. | Institution (13F) | 15,668,529 | 1.28% | 2026-09-30 |
| Morgan Stanley | Institution (13F) | 14,900,060 | 1.22% | 2026-09-30 |
| Fisher Asset Management, LLC | Institution (13F) | 9,597,228 | 0.79% | 2026-09-30 |
| Bank of America Corporation | Institution (13F) | 7,840,212 | 0.64% | 2026-09-30 |
| JPMORGAN CHASE & CO | Institution (13F) | 7,330,737 | 0.60% | 2026-09-30 |
| Invesco Ltd. | Institution (13F) | 6,271,955 | 0.51% | 2026-09-30 |
| Mondrian Investment Partners Ltd | Institution (13F) | 5,652,139 | 0.46% | 2026-09-30 |
| Federated Hermes, Inc. | Institution (13F) | 5,455,928 | 0.45% | 2026-09-30 |
| Brandes Investment Partners L.P. | Institution (13F) | 4,306,275 | 0.35% | 2026-09-30 |
| Boston Partners | Institution (13F) | 3,999,818 | 0.33% | 2026-09-30 |
| FMR, LLC | Institution (13F) | 3,967,153 | 0.33% | 2026-09-30 |
Share count 1,219,427,096 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SNY and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →